Background: The duration of antacid-induced hypergastrinemia after cessation of administration of omeprazole and famotidine apparently has not been determined in dogs.

Hypothesis: That serum gastrin will return to basal concentrations by 7 days after cessation of famotidine or omeprazole administration.

Animals: Nine healthy, adult, male, research colony dogs.

Methods: Randomized, cross-over design. Serum gastrin was determined daily for 7 days to establish baseline concentrations. Famotidine (1.0 mg/kg q24h) or omeprazole (1.0 mg/kg q24h) was administered PO for 7 days followed by a 14-day washout. Serum concentrations of gastrin were determined daily during 7 days of administration and daily for 7 days after cessation of administration. Each drug was evaluated in 8 of the 9 dogs.

Results: Omeprazole caused a significant increase in serum gastrin concentration (37.2 ± 7.3 to 71.3 ± 19.0 ng/L; P = .006). Famotidine induced a transient increase in serum gastrin (37.2 ± 7.3 to 65.5 ± 38.5 ng/L; P = .02) that peaked at administration day 3 and declined thereafter. By day 7 after cessation of both drugs, there was no difference in serum gastrin concentrations compared to those before administration (famotidine P = .99; omeprazole P = .99). During or after administration, gastrin concentrations above 3 times the upper reference range were rare (12 of 224 samples).

Conclusions And Clinical Importance: A 7-day withdrawal from short-term administration of famotidine or omeprazole is sufficient for serum gastrin to return to baseline concentrations. Withholding famotidine or omeprazole for longer before investigating pathologic causes of hypergastrinemia is unnecessary.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4895597PMC
http://dx.doi.org/10.1111/jvim.12408DOI Listing

Publication Analysis

Top Keywords

serum gastrin
24
famotidine omeprazole
20
daily days
12
gastrin
9
serum
8
serum concentrations
8
concentrations gastrin
8
famotidine
8
omeprazole
8
administration
8

Similar Publications

Aims: This study aims to assess the serum levels of pepsinogen (PG)I, PG II, and gastrin (G17) in patients with gastric intestinal metaplasia (GIM) and evaluate their correlation with demographic characteristics.

Methods: A total of 247 normal controls (NC) and 240 patients diagnosed with GIM were enrolled in this study. All participants underwent a gastroscopy procedure followed by pathological examination for diagnosis confirmation.

View Article and Find Full Text PDF

Objective: Urinary proteins are effective tumor biomarkers. Human epididymis protein 4 (HE4), progastrin-releasing peptide (ProGRP), carcinoembryonic antigen (CEA), cytokeratin-19 fragment 21-1(CYFRA 21-1), and neuron-specific enolase (NSE) in serum, were proposed as tumor biomarkers of lung cancer. Our aim was to identify the urine protein biomarkers that can distinguish patients with lung cancer from healthy individuals and/or patients with benign lung disease with a high level of sensitivity and specificity.

View Article and Find Full Text PDF

Serum levels of PSA and VEGF2 as the prognosis markers for bone metastasis of prostate cancer: A retrospective study.

Comput Biol Chem

December 2024

Department of Emergency, Wuhan No.6 Hospital(Affiliated Hospital of Jianghan University), No.168, Xianggang Road, Jiangan District, Wuhan, Hubei 430015, China. Electronic address:

Background And Objective: Prostate cancer (PCa) is the second most commonly diagnosed cancer in males, the mechanism of PCa with bone metastasis remains unclear. In this study, we aimed to utilize a retrospective clinical study to evaluate the diagnostic value of bone metastases from PCa and provide reference values for future applications.

Methods: We retrospectively collected a total of 200 samples including 100 PCa patients with bone metastatic and 100 without from June 2019 to August 2021.

View Article and Find Full Text PDF

Background: YYD601 is a new dual delayed-release formulation of esomeprazole, developed to enhance plasma exposure and prolong the duration of acid suppression.

Purpose: This study aimed to evaluate the safety, pharmacokinetic (PK), and pharmacodynamic (PD) profiles of YYD601 20 mg following single and multiple oral administrations in healthy, fasting adult Koreans, and to compare these outcomes to those of the conventional esomeprazole 20 mg capsule.

Methods: A randomized, open-label, two-period crossover study was conducted in 28 participants, who were divided into two treatment groups: one group received YYD601 20 mg, and the other received conventional esomeprazole 20 mg, once daily for five consecutive days.

View Article and Find Full Text PDF
Article Synopsis
  • The article evaluates the effectiveness and safety of a combination treatment of atropine (ATR) and omeprazole (OME) for acute gastritis (AG) in comparison to anisodamine (ADM) with OME.
  • The study involved 95 patients, with the ATR+OME group showing a higher success rate, fewer side effects, and quicker symptom relief than the ADM+OME group.
  • Results indicated that the ATR+OME treatment significantly reduced inflammatory markers and gastrointestinal hormone levels, suggesting its strong efficacy and safety for managing AG, making it suitable for wider clinical use.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!